Enfusion, Inc. (ENFN)
NYSE: ENFN · IEX Real-Time Price · USD
9.25
-0.18 (-1.91%)
At close: Jul 19, 2024, 4:00 PM
10.60
+1.35 (14.58%)
After-hours: Jul 20, 2024, 1:30 PM EDT
Enfusion Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Enfusion stock have an average target of 9.33, with a low estimate of 8.00 and a high estimate of 11. The average target predicts an increase of 0.86% from the current stock price of 9.25.
Analyst Consensus: Sell
* Price targets were last updated on Mar 13, 2024.
Analyst Ratings
The average analyst rating for Enfusion stock from 6 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Sell Maintains $8 → $9 | Sell | Maintains | $8 → $9 | -2.70% | Mar 13, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $9 → $8 | Hold → Strong Sell | Downgrades | $9 → $8 | -13.51% | Feb 28, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades $11 → $9 | Hold → Sell | Downgrades | $11 → $9 | -2.70% | Jan 30, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $9 → $10 | Hold | Maintains | $9 → $10 | +8.11% | Dec 20, 2023 |
| UBS | UBS | Hold Initiates $9 | Hold | Initiates | $9 | -2.70% | Nov 7, 2023 |
Financial Forecast
Revenue This Year
209.68M
from 174.54M
Increased by 20.14%
Revenue Next Year
248.15M
from 209.68M
Increased by 18.35%
EPS This Year
0.25
from 0.07
Increased by 257.00%
EPS Next Year
0.34
from 0.25
Increased by 37.76%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 220.5M | 265.7M | 315.6M |
| Avg | 209.7M | 248.2M | 288.8M |
| Low | 198.2M | 229.2M | 263.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 26.3% | 26.7% | 27.2% |
| Avg | 20.1% | 18.3% | 16.4% |
| Low | 13.6% | 9.3% | 6.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.38 | 0.53 | 0.36 |
| Avg | 0.25 | 0.34 | 0.32 |
| Low | 0.17 | 0.21 | 0.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 440.0% | 110.1% | 3.7% |
| Avg | 257.0% | 37.8% | -7.2% |
| Low | 138.0% | -17.6% | -14.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.